Article Text

GW24-e0006 The myeloperoxidase -463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls
  1. Chang Cuixian,
  2. Jiang Guoqiang
  1. Department of Cardiology, Sichuan Province Hospital of CAPF, Leshan, China 614000


Objectives Genetic polymorphism of human myeloperoxidase (MPO) -463G/A has been implicated to alter the risk of coronary artery disease (CAD), but the results are controversial. To improve the reliability of the conflicting results, we conducted a meta-analysis of studies relating the MPO -463G/A polymorphism with the risk of CAD.

Methods Two investigators independently searched the MEDLINE, EMBASE and Cochrane Library up to June, 2012. Summary odds ratios (OR) and 95% confidence interval (CI) for the MPO -463G/A polymorphism and CAD risk were calculated, and potential sources of heterogeneity and publication bias were explored. Statistical analysis was performed with the software program of Stata 9.0.

Results 5 case-control studies were finally identified for analyses, involving 1938 cases with CAD and 1990 controls. We found that the MPO -463G/A polymorphism has no significant association with overall CAD risk (G/G vs A/A: OR = 0.595, 95%CI = 0.298-1.188, P = 0.141; G/G vs G/A + A/A: OR = 0.886, 95%CI = 0.779-1.008, P = 0.066; G/G + G/A vs A/A: OR = 0.611, 95%CI = 0.334-1.119, P = 0.111; OR = 0.886, 95%CI = 0.779-1.008, P = 0.066; G vs A: OR = 0.843, 95%CI = 0.675-1.053, P = 0.133). The heterogeneity test showed that there were significant differences between individual studies in additive, recessive and allelic genetic model (P = 0.008, P = 0.021, P = 0.019, respectively), further analyses revealed that age and sex possibly account for the heterogeneity.

Conclusions Our meta-analysis demonstrated the evidence that there was no significant association between the MPO -463G/A polymorphism and the risk of CAD, larger and well-designed multicentre studies are needed to confirm our results.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.